Skip to content

A randomized controlled clinical study of the treatment of patients with microvascular angina, qi stagnation, phlegm obstruction, and blood stasis syndrome

A randomized controlled clinical study of the treatment of patients with microvascular angina, qi stagnation, phlegm obstruction, and blood stasis syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087241
Enrollment
Unknown
Registered
2024-07-23
Start date
2024-07-31
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microvascular angina

Interventions

Experimental Group:Standardized Western medicine treatment combined with Liqi Huatan Huoxue formula

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria of microvascular angina; 2) Age 18-79 years old; 3) TCM syndrome differentiation is consistent with qi stagnation and phlegm obstruction and blood stasis pattern; 4) Have not taken Chinese medicine within 1 week; 5) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with one of the following diseases: ST elevation changes on ECG, or coronary spasm on coronary angiography; After PCI, after coronary artery bypass, old myocardial infarction; myocardial bridge; Degree II. type II or above sinus or atrioventricular block with no pacemaker implanted, difficult-to-control malignant arrhythmia; dilated cardiomyopathy, hypertrophic obstructive cardiomyopathy, myocarditis, pulmonary embolism, severe valvular disease, cor pulmonale; 2) Patients with non-cardiogenic chest pain caused by pleura, gastrointestinal tract, intercostal neuralgia and other diseases; 3) Patients with endocrine diseases such as diabetes mellitus and hyperthyroidism, severe anemia (hemoglobin =9g/dl), and other diseases that affect survival (such as malignant tumors); 4) Patients with abnormal liver and kidney function (alanine aminotransferase, aspartate aminotransferase or serum creatinine is more than 2 times higher than the upper limit of normal); 5) Those who are allergic to the test drug; 6) Those who have participated in other drug clinical studies in the past 2 months; 7) Women who are pregnant, planning to become pregnant, or breastfeeding; 8) Those who are considered inappropriate by the investigators to participate in the study.

Design outcomes

Primary

MeasureTime frame
Peak oxygen consumption;Seattle Angina Questionnaire (SAQ) Score;

Secondary

MeasureTime frame
Cardiopulmonary exercise test: oxygen uptake (VO2), metabolic equivalent, O2 Pulse, Exercise load (watt), Exercise time, Hate rate, etc;Syndrome scoring table of Traditional Chinese Medicine;

Countries

China

Contacts

Public ContactXIANLIANG WANG

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

xlwang1981@126.com+86 139 2000 7825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026